For treatment-eligible patients with newly diagnosed FLT3-ITD+ AML Start and stay with VANFLYTA—The only FLT3 inhibitor indicated for INDUCTION, CONSOLIDATION, AND MAINTENANCE1-3* *Please see Full Indication, including Limitations of Use, below.

VANFLYTA is a once-daily oral treatment from induction through consolidation and maintenance1*

VANFLYTA Dosing Snapshot1

Image showing the VANFLYTA Dosing Snapshot across all 3 treatment phases. VANFLYTA should be administered once daily orally with or without food. Swipe to the left
Image showing the VANFLYTA Dosing Snapshot across all 3 treatment phases. VANFLYTA should be administered once daily orally with or without food.

For patients who proceed to HSCT, VANFLYTA should be stopped 7 days before the start of a conditioning regimen.1

*Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic HSCT; improvement in overall survival with VANFLYTA in this setting has not been demonstrated.1

†For 5+2 regimen as the second induction cycle, VANFLYTA will be given on Days 6-19.1

Tablets shown are not actual size.

Induction: 35.4 mg orally once daily on Days 8-21 of 7+3 (cytarabine [100 or 200 mg/m2/day] on Days 1-7 plus daunorubicin [60 mg/m2/day] or idarubicin [12 mg/m2/day] on Days 1-3) and on Days 8-21 or 6-19 of an optional second induction (7+3 or 5+2 [5 days cytarabine plus 2 days daunorubicin or idarubicin], respectively).1

Consolidate: 35.4 mg orally once daily on Days 6-19 of high-dose cytarabine (1.5 to 3.0 g/m2 every 12 hours on Days 1, 3, and 5) for up to 4 cycles.1

Maintenance: 26.5 mg orally once daily on Days 1-14 and 53 mg orally once daily thereafter for up to thirty-six 28-day cycles.1

Dosing VANFLYTA with standard chemotherapy1

ECG and electrolyte monitoring1

clipboard with pen icon

Prior to Initiation of Treatment

Do not start treatment with VANFLYTA if the QTcF interval is >450 ms.1

clipboard with check mark icon

Prior to and During Treatment

Monitor and correct hypokalemia and hypomagnesemia. Maintain electrolytes in the normal range. Monitor electrolytes and perform ECGs more frequently in patients who experience diarrhea or vomiting.1

ECG monitoring icon

ECG Monitoring

Perform ECG monitoring of the QT interval more frequently in patients who are at significant risk of developing QT interval prolongation and torsades de pointes, or following dose escalation.1

VANFLYTA patient recommendations for administration1

meal icon

Take orally with or without food1

clock icon

Take at approximately
the same time each day1

crushed pill with line crossed out icon

Swallow tablets whole. Do not cut, crush, or chew the tablets1

vomit icon

If VANFLYTA is vomited, do not administer a replacement dose; wait until the next scheduled dose1

VANFLYTA dosing icon

If a dose of VANFLYTA is missed or not taken at the usual time, administer the dose as soon as possible on the same day and return to the normal schedule the following day1

pill 2x with line crossed out icon

Do not take 2 doses on the same day1

VANFLYTA offers once-daily dosing1

VANFLYTA offers once-daily dosing1

VANFLYTA® (quizartinib) prescription boxes: 17.7mg and 26.5mg

Not actual size.

DOWNLOAD
DOSING GUIDE
VANFLYTA® (quizartinib) prescription boxes: 17.7mg and 26.5mg

Not actual size.

VANFLYTA dose adjustments may follow an approach that meets your patient’s needs1

RECOMMENDED DOSE ADJUSTMENTS FOR ARs DURING VANFLYTA TREATMENT1*

A chart outlining modified dose recommendations for adverse reactions during VANFLYTA treatment A chart outlining modified dose recommendations for adverse reactions during VANFLYTA treatment

DOSE ADJUSTMENTS FOR CONCOMITANT USE WITH STRONG INHIBITORS1*

A chart outlining dose modifications for concomitant use with strong inhibitors A chart outlining dose modifications for concomitant use with strong inhibitors

*Tablets should be taken orally once daily with or without food at approximately the same time each day.1

If the current dosage is 17.7 mg once daily, interrupt VANFLYTA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the VANFLYTA dose that was taken before initiating the strong inhibitor1

RECOMMENDED DOSAGE MODIFICATIONS FOR ARs1

A chart outlining recommended dosage modifications for adverse reactions Swipe to the left
A chart outlining recommended dosage modifications for adverse reactions

*Recommend bone marrow evaluation.1

Grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 (NCI CTCAE v4.03).

Access Vanflyta
Resources

VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)–positive as detected by an FDA-approved test.

Limitations of Use: VANFLYTA is not indicated as maintenance monotherapy following allogeneic hematopoietic stem cell transplantation (HSCT); improvement in overall survival with VANFLYTA in this setting has not been demonstrated.

AML=acute myeloid leukemia; AR=adverse reaction; CYP3A=cytochrome P450 3A; ECG=electrocardiogram; FLT3=FMS (feline McDonough sarcoma)–like tyrosine kinase 3; HSCT=hematopoietic stem cell transplantation; ITD=internal tandem duplication; QTcF=the QT interval corrected by Fridericia's formula.

References:

1. VANFLYTA [package insert]. Basking Ridge, NJ: Daiichi Sankyo, Inc; 2024.  2. XOSPATA [package insert]. Northbrook, IL: Astellas Pharma US, Inc; 2022. 3. RYDAPT [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2023.